Taysha Gene Therapies, Inc. TSHA
4.67
(0.12)
(2.51%)
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow TSHA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
P/S ratio |
149.08 | 51.93 | 12.85 | 0.00 | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
P/Operating CF |
(65.80) | (23.64) | (12.32) | 6.57 | — | — | — | — |
P/B ratio |
7.12 | 6.05 | 2.65 | 101.89 | — | — | — | — |
Price to Tangible BV |
7.12 | 6.05 | 2.65 | 101.89 | — | — | — | — |
EV/Sales |
126.18 | 40.46 | 6.13 | 0.00 | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
EV/Operating CF |
(15.99) | (4.15) | (1.30) | (0.53) | — | — | — | — |
EV/FCF |
(15.14) | (3.92) | (1.16) | (0.41) | — | — | — | — |
Quick Ratio |
12.06 | 5.32 | 3.93 | 1.40 | 2.88 | 35.24 | 0.00 | — |
Current Ratio |
12.23 | 5.42 | 4.08 | 1.54 | 3.08 | 36.17 | 0.10 | — |
Net Debt/EBITDA |
2.47 | 1.06 | 1.46 | 0.31 | 0.65 | 5.84 | 0.00 | — |
Debt/Assets |
14.59% | 27.40% | 23.45% | 30.07% | 17.38% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.20 | 0.61 | 0.54 | 40.01 | 0.39 | 0.00 | 0.00 | — |
Asset Turnover |
0.04 | 0.05 | 0.10 | 0.01 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.85 | 0.91 | 0.65 | 0.53 | 0.67 | 0.51 | 0.00 | — |
Capex/Depreciation |
(0.64) | (0.30) | (5.37) | (21.22) | (43.81) | (1,009.11) | 0.00 | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (68.45%) | (121.94%) | (294.04%) | (344.67%) | (100.68%) | (47.79%) | (0.89%) | — | |
| (43.28%) | (53.62%) | (74.62%) | (97.59%) | (73.82%) | (46.36%) | (14,866.67%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (54,849.49%) | 0.00% | — |
Return on Tangible Assets |
(35.76%) | (72.37%) | (90.02%) | (341.66%) | (110.13%) | (23.91%) | 825.93% | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
884.10% | 792.04% | 367.47% | 3,643.84% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
346.55% | 347.45% | 194.47% | 1,493.21% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
136.07% | 157.24% | 51.16% | 721.14% | 0.00% | 0.00% | — | — |
Graham Net Nets |
0.13 | 0.12 | 0.26 | (0.30) | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Earnings Yield |
(6.18%) | (20.81%) | (39.18%) | (171.82%) | — | — | — | — |
Free Cash Flow Yield |
(5.59%) | (19.90%) | (40.99%) | (117.13%) | — | — | — | — |
Revenue per Share |
0.03 | 0.03 | 0.13 | 0.06 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.29) | (0.32) | (0.63) | (2.01) | (3.11) | (1.74) | 0.00 | — |
Capex per Share |
0.00 | 0.00 | (0.06) | (0.57) | (0.57) | (0.51) | 0.00 | — |
Free Cash Flow per Share |
(0.29) | (0.33) | (0.69) | (2.58) | (3.68) | (2.25) | 0.00 | — |
Cash per Share |
1.00 | 0.56 | 1.24 | 2.00 | 3.96 | 14.22 | 0.00 | — |
Shareholders Equity per Share |
0.77 | 0.29 | 0.65 | 0.02 | 2.53 | 14.23 | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.77 | 0.29 | 0.65 | 0.02 | 2.53 | 14.23 | 0.00 | — |
Free Cash Flow |
(93.83) | (81.60) | (80.39) | (113.26) | (138.60) | (39.81) | 0.00 | — |
Working Capital |
298.10 | 115.90 | 113.11 | 33.63 | 107.86 | 250.75 | (0.13) | — |
Capital Expenditures |
(0.74) | (0.37) | (7.37) | (24.87) | (21.55) | (9.08) | 0.00 | — |
Net Current Asset Value |
228.27 | 53.29 | 52.07 | (28.91) | 41.03 | 250.30 | (0.13) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Capex to Sales |
0.08 | 0.04 | 0.48 | 9.94 | 0.00 | 0.00 | 0.00 | — |
Net Profit Margin |
(1,115.27%) | (1,071.62%) | (722.06%) | (6,635.25%) | 0.00% | 0.00% | 0.00% | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.17 | 0.17 | 0.13 | 0.08 | 0.01 | 0.03 | 0.00 | — |
Cash ROIC |
(16.17%) | (34.79%) | (32.27%) | (81.51%) | (59.52%) | (6.17%) | 0.00% | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Average Payables |
4.93 | 4.98 | 8.66 | 16.35 | 11.88 | — | — | — |
Average Assets |
251.84 | 166.55 | 149.50 | 170.12 | 236.42 | 129.45 | 0.01 | — |
Average Common Equity |
159.23 | 73.23 | 37.94 | 48.17 | 173.34 | 125.58 | 125.58 | — |
Columns are period end dates